866-997-4948(US-Canada Toll Free)

Comtan - Analysis and Estimates from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 37 Pages


GlobalDatas pharmaceuticals report, Comtan Analysis and Estimates from 2002 to 2020 provides Comtan sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Comtan including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Comtan including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Comtan in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 Comtan 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 16
6.4 Approval History of Comtan 18
6.5 Factors Affecting Sales of Comtan 18
6.5.1 Novel COMT Inhibitor 18
6.5.2 Higher Safety Profile among Class 18
6.5.3 Entry of Generics 18
6.5.4 Higher Persistence Rates 19
6.5.5 Shift in Patients Pool 19
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Forecasts 22
6.7.1 Target Patient Pool of Parkinsons Disease 22
6.7.2 Dosing 22
6.7.3 Market Penetration 22
6.7.4 Annual Cost of Therapy 23
6.7.5 Sales Projections of Comtan 24

7 Parkinson Disease Market: Appendix 33
7.1 Market Definitions 33
7.2 List of Abberiviations 33
7.3 Research Methodology 33
7.3.1 Coverage 33
7.3.2 Secondary Research 33
7.3.3 Forecasting 34
7.3.4 Number of Patients Approved to take the Drug 34
7.3.5 Net Penetration of Drug 34
7.3.6 Net Annual Dosing 35
7.3.7 Annual Cost of Therapy 35
7.3.8 Primary Research 36
7.3.9 Expert Panels 36
7.4 Drug Sales Estimates Model 36
7.5 Contact Us 36
7.6 Disclaimer 37
7.7 Sources 37

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of Parkinsons disease 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 14
Table 9: Nordic Study - Primary Measure 16
Table 10: Nordic Study - Secondary Measures 16
Table 11: German-Austrian Study - Primary Measure 17
Table 12: German-Austrian Study Secondary Measure 17
Table 13: Approval History of Comtan 18
Table 14: Drug Risk Benefit Score 19
Table 15: Efficacy Comparison of Comptan vs. Tasmar 20
Table 16: Safety Comparison of Comtan vs. Tasmar 21
Table 17: Efficacy Comparison of Comtan 21
Table 18: Annual Cost of Therapy (2010) 23
Table 19: Comtan, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 24
Table 20: Comtan, Parkinsons Disease, The US, Sales Estimates ($m), 20022020 25
Table 21: Comtan, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 26
Table 22: Comtan, Parkinsons Disease, France, Sales Estimates ($m), 20022020 27
Table 23: Comtan, Parkinsons Disease, Germany, Sales Estimates ($m), 20022020 28
Table 24: Comtan, Parkinsons Disease, Italy, Sales Estimates ($m), 20022020 29
Table 25: Comtan, Parkinsons Disease, Spain, Sales Estimates ($m), 20022020 30
Table 26: Comtan, Parkinsons Disease, Japan, Sales Estimates ($m), 20072020 31

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 14
Figure 7: Mechanism of COMT Inhibitor 15
Figure 8: Drug Model Diagram of Comtan 22
Figure 9: Comtan, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 24
Figure 10: Comtan, Parkinsons Disease, The US, Sales Estimates ($m), 20022020 25
Figure 11: Comtan, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 26
Figure 12: Comtan, Parkinsons Disease, France, Sales Estimates ($m), 20022020 27
Figure 13: Comtan, Parkinsons Disease, Germany, Sales Estimates ($m), 20022020 28
Figure 14: Comtan, Parkinsons Disease, Italy, Sales Estimates ($m), 20022020 29
Figure 15: Comtan, Parkinsons Disease, Spain, Sales Estimates ($m), 20022020 30
Figure 16: Comtan, Parkinsons Disease, Japan, Sales Estimates ($m), 20072020 31
Figure 17: Comtan, Parkinsons Disease, Sales Distribution by Country($m), 2011 32
Figure 18: Drug Model Diagram 35
Figure 19: Patients Approved for the Drug 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *